MX2020006395A - Radioetiquetado de polipeptidos. - Google Patents

Radioetiquetado de polipeptidos.

Info

Publication number
MX2020006395A
MX2020006395A MX2020006395A MX2020006395A MX2020006395A MX 2020006395 A MX2020006395 A MX 2020006395A MX 2020006395 A MX2020006395 A MX 2020006395A MX 2020006395 A MX2020006395 A MX 2020006395A MX 2020006395 A MX2020006395 A MX 2020006395A
Authority
MX
Mexico
Prior art keywords
radiolabeling
polypeptides
methods
pharmaceutical compositions
antibodies
Prior art date
Application number
MX2020006395A
Other languages
English (en)
Inventor
Shalom Goldberg
Rhys Salter
Vadim Dudkin
Joseph Erhardt
Theresa M Mcdevitt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2020006395A publication Critical patent/MX2020006395A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos mejorados para radioetiquetar anticuerpos usando química clic; también se describen composiciones farmacéuticas y usos relacionados con los anticuerpos radioetiquetados producidos a través de los métodos.
MX2020006395A 2017-12-18 2018-12-17 Radioetiquetado de polipeptidos. MX2020006395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599830P 2017-12-18 2017-12-18
PCT/US2018/065913 WO2019125982A1 (en) 2017-12-18 2018-12-17 Radiolabeling of polypeptides

Publications (1)

Publication Number Publication Date
MX2020006395A true MX2020006395A (es) 2020-12-03

Family

ID=65003549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006395A MX2020006395A (es) 2017-12-18 2018-12-17 Radioetiquetado de polipeptidos.

Country Status (15)

Country Link
US (1) US20210017099A1 (es)
EP (1) EP3727474A1 (es)
JP (2) JP2021506842A (es)
KR (1) KR20200100094A (es)
CN (1) CN111491670A (es)
AU (1) AU2018388467A1 (es)
BR (1) BR112020012099A2 (es)
CA (1) CA3085465A1 (es)
EA (1) EA202091420A1 (es)
IL (1) IL275242A (es)
MX (1) MX2020006395A (es)
PH (1) PH12020550690A1 (es)
SG (1) SG11202004906QA (es)
WO (1) WO2019125982A1 (es)
ZA (1) ZA202004424B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52777A (fr) * 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
WO2020229974A1 (en) 2019-05-10 2020-11-19 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
CA3148952C (en) * 2019-07-30 2024-01-16 Jfe Engineering Corporation Method for synthesizing zirconium complex
CN114555132A (zh) 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
KR20220114616A (ko) * 2020-01-16 2022-08-17 제이에프이 엔지니어링 가부시키가이샤 지르코늄 착체의 합성 방법
PE20230001A1 (es) 2020-03-13 2023-01-05 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
WO2021236716A2 (en) * 2020-05-19 2021-11-25 Board Of Regents, The University Of Texas System Methods, systems and kits for polypeptide processing and analysis
TW202233247A (zh) 2020-10-16 2022-09-01 日商日本醫事物理股份有限公司 抗ｈｅｒ２抗體之放射性複合體及放射性醫藥
US20240166631A1 (en) 2021-03-26 2024-05-23 Nihon Medi-Physics Co., Ltd Compound, method for producing and method for storing compound, method for producing targeting agent, and composition
JPWO2022211051A1 (es) * 2021-03-31 2022-10-06
EP4337254A1 (en) * 2021-05-11 2024-03-20 Northeastern University Site-specific modification of glycoproteins through transglutaminase-mediated conjugation
WO2023190402A1 (ja) * 2022-03-30 2023-10-05 日本メジフィジックス株式会社 複合体の製造方法
WO2024030772A1 (en) * 2022-08-01 2024-02-08 Portland State University High relaxivity contrast agents and stereoselective preparation
WO2024059908A1 (en) * 2022-09-21 2024-03-28 The University Of Melbourne Radiolabelled compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
WO2011008990A1 (en) * 2009-07-15 2011-01-20 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
WO2012012612A2 (en) 2010-07-23 2012-01-26 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
CN103221072A (zh) * 2010-12-02 2013-07-24 免疫医疗公司 用于递送治疗剂和/或诊断剂的体内无铜催化的点击化学
WO2013003555A1 (en) * 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
EP2912459A2 (en) * 2012-10-25 2015-09-02 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
JP2016538878A (ja) * 2013-10-14 2016-12-15 シンアフィックス ビー．ブイ． 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
WO2016054277A1 (en) * 2014-09-30 2016-04-07 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Cu(i)-catalyzed azide-alkyne cycloadditions (cuaac) ligands and methods for carrying out cu(i)-catalyzed azide- alkyne cycloaddition reactions
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes

Also Published As

Publication number Publication date
JP2023078366A (ja) 2023-06-06
AU2018388467A1 (en) 2020-06-11
ZA202004424B (en) 2022-06-29
BR112020012099A2 (pt) 2020-11-17
KR20200100094A (ko) 2020-08-25
EP3727474A1 (en) 2020-10-28
SG11202004906QA (en) 2020-07-29
EA202091420A1 (ru) 2020-09-10
IL275242A (en) 2020-07-30
PH12020550690A1 (en) 2021-04-12
WO2019125982A1 (en) 2019-06-27
US20210017099A1 (en) 2021-01-21
CA3085465A1 (en) 2019-06-27
CN111491670A (zh) 2020-08-04
JP2021506842A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
PH12020550690A1 (en) Radiolabeling of polypeptides
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA202190808A2 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2021001841A (es) Anticuerpos anti-gdf15, composiciones y metodos de uso.
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
MY191581A (en) Anti-pd-1 antibodies
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2019015744A (es) Composiciones farmaceuticas.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EA201992027A1 (ru) Водный состав антитела против pd-l1
PH12017502277A1 (en) Multi-specific binding proteins
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
PH12019502694A1 (en) Anti-trkb antibodies
MX2018009218A (es) Anticuerpos de cgrp y sus usos.